share_log

HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21

HC Wainwright & Co. Maintains Buy on Redhill Biopharma, Lowers Price Target to $21

HC Wainwright&Co.维持在Redhill Biophma的买入,将目标价下调至21美元
Benzinga Real-time News ·  2021/09/15 06:08

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Redhill Biopharma (NASDAQ:RDHL) with a Buy and lowers the price target from $23 to $21.

HC Wainwright&Co.分析师Raghuram Selvaraju维持Redhill Biophma(纳斯达克股票代码:RDHL)的买入,并将目标价从23美元下调至21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发